Small-molecule protein kinase inhibitors represent an increasingly successful therapeutic strategy for a range of cancer types with over 50 FDA-approved protein kinase inhibitors in clinical use [2,3,4] and hundreds more undergoing clinical or preclinical trials. Here, WEE1 is linked to cancer.